The present invention relates to methods and compositions comprising
compounds that treat pathophysiological conditions arising from
inflammatory responses. In particular, the present invention is directed
to compounds that inhibit or block glycated protein produced induction of
the signaling-associated inflammatory response in endothelial cells. The
present invention relates to compounds that inhibit smooth muscle
proliferation. In particular, the present invention is directed to
compounds that inhibit smooth muscle cell proliferation by modulating
HSPGs such as Perlecan. The present invention further relates to the use
of compounds to treat vascular occlusive conditions characterized by
smooth muscle proliferation such as restenosis and atherosclerosis.
